James Marks, M.D., Ph.D.

Dr. James Marks is recognized as a pioneer and leader in the field of antibody engineering. He currently serves as a Professor and Vice-Chairman of the Department of Anesthesia and Perioperative Care at the University of California, San Francisco and Chief of the Medical Staff and Chief of Anesthesia at Zuckerberg San Francisco General Hospital and Trauma Center. He also operates the Marks Lab at UCSF, conducting research that focuses on the generation of recombinant antibodies, mostly fully human, that can be used in the diagnosis and treatment of cancers and other human diseases, or to capture or neutralize toxins.

Dr. Marks has extensive experience in the biotechnology industry, having co-founded Hermes Biosciences, an early-stage biotechnology company focused on the development of antibody targeted immunoliposomes for cancer therapy that was acquired by Merrimack Pharmaceuticals in 2009. Dr. Marks serves on several biopharmaceutical scientific advisory boards, has more than 180 publications in the field and is an inventor on more than 100 issued or pending patents. Dr. Marks received his medical degree from UCSF where he also completed residencies in Internal Medicine and Anesthesia and a fellowship in Critical Care Medicine.  He received his Ph.D. in molecular biology from the Medical Research Council Laboratory of Molecular Biology in Cambridge, England.